Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:INABNASDAQ:NAGENASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.26+0.9%$7.99$5.20▼$10.67$1.11B1.151.33 million shs354,379 shsINABIN8bio$2.19-3.1%$4.40$2.13▼$34.50$6.62M0.18180,083 shs150,641 shsNAGENiagen Bioscience$13.99+2.6%$9.25$2.31▼$14.49$1.10B2.08854,236 shs425,454 shsWVEWave Life Sciences$6.87-1.2%$6.52$4.25▼$16.74$1.06B-1.041.23 million shs126,623 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%-0.12%-0.12%-2.62%+44.78%INABIN8bio0.00%-45.80%-41.47%-66.70%-93.09%NAGENiagen Bioscience0.00%+5.25%+24.47%+71.66%+357.38%WVEWave Life Sciences0.00%-3.74%+9.79%-31.66%+11.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.286 of 5 stars3.52.00.00.04.10.81.9INABIN8bio3.5739 of 5 stars3.55.00.00.03.22.50.6NAGENiagen Bioscience1.4363 of 5 stars3.50.00.00.02.60.00.0WVEWave Life Sciences4.2667 of 5 stars3.51.00.04.82.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5039.31% UpsideINABIN8bio 3.00Buy$180.008,119.18% UpsideNAGENiagen Bioscience 3.00Buy$19.5039.39% UpsideWVEWave Life Sciences 2.92Moderate Buy$20.50198.40% UpsideCurrent Analyst Ratings BreakdownLatest INAB, AUPH, WVE, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025WVEWave Life SciencesRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.006/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.004/29/2025WVEWave Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/8/2025WVEWave Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.003/26/2025WVEWave Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.51N/AN/A$2.63 per share3.14INABIN8bioN/AN/AN/AN/A$0.58 per shareN/ANAGENiagen Bioscience$107.93M10.21N/AN/AN/A∞WVEWave Life Sciences$104.94M10.09N/AN/A$0.40 per share17.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.74N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)INABIN8bio-$30.01M-$13.57N/AN/AN/AN/A-197.15%-130.48%8/14/2025 (Estimated)NAGENiagen BioscienceN/A$0.1782.29∞N/AN/AN/AN/AN/AWVEWave Life Sciences-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%8/6/2025 (Estimated)Latest INAB, AUPH, WVE, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q1 2025INABIN8bio-$1.80-$2.10-$0.30-$0.07N/AN/A5/8/2025Q1 2025WVEWave Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/AWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11INABIN8bio0.051.841.84NAGENiagen BioscienceN/AN/AN/AWVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%INABIN8bio92.05%NAGENiagen Bioscience15.41%WVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%INABIN8bio15.50%NAGENiagen Bioscience9.39%WVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableINABIN8bio203.02 million61.25 millionNot OptionableNAGENiagen Bioscience12078.77 millionN/AN/AWVEWave Life Sciences240154.13 million108.14 millionOptionableINAB, AUPH, WVE, and NAGE HeadlinesRecent News About These CompaniesWave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in StockJune 14 at 7:51 AM | insidertrades.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Average Target Price from AnalystsJune 14 at 2:20 AM | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 SharesJune 13 at 8:41 PM | marketbeat.comWave Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at Raymond JamesJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Comments on WVE FY2026 EarningsJune 12, 2025 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Now Covered by Raymond JamesJune 11, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from AnalystsJune 11, 2025 | marketbeat.comBrokers Offer Predictions for WVE FY2026 EarningsJune 10, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's WhyJune 9, 2025 | marketbeat.comTwo Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)June 3, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)June 2, 2025 | marketbeat.comNuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 31, 2025 | marketbeat.comWave Life Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LPMay 29, 2025 | marketbeat.comBank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 29, 2025 | marketbeat.comWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical OfficerMay 28, 2025 | globenewswire.comPolar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 28, 2025 | marketbeat.com845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLCMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 20, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust CorpMay 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Red Robin's Comeback: Q1 Earnings Spark Investor HopesBy Jeffrey Neal Johnson | June 5, 2025View Red Robin's Comeback: Q1 Earnings Spark Investor HopesINAB, AUPH, WVE, and NAGE Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.26 +0.08 (+0.92%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.IN8bio NASDAQ:INAB$2.19 -0.07 (-3.10%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Niagen Bioscience NASDAQ:NAGE$13.99 +0.36 (+2.64%) As of 12:34 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Wave Life Sciences NASDAQ:WVE$6.87 -0.08 (-1.15%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
